BioCentury | Oct 22, 2020
Product Development

CRISPR’s data hint allogeneic CAR Ts may have the efficacy and safety issues of autologous therapies

...GvHD.In addition to inserting the CAR into TRAC to prevent GvHD, CTX110 has a CRISPR-mediated B2M...
BioCentury | Feb 26, 2019
Distillery Techniques

Drug platforms

...or sequential CRISPR-Cas9 (CRISPR-associated protein 9)-mediated deletion in an iPS cell line of β-2 microglobulin (B2M...
...University of California San Francisco, San Francisco, Calif. email: Sonja.Schrepfer@ucsf.edu Sandi Wong University of California San Francisco Beta-2 microglobulin (B2M) CD47 Class...
BioCentury | Feb 1, 2019
Tools & Techniques

TMB needs company

...Moreover, a 2017 Nature Communications paper showed point mutations, deletions and loss of heterozygosity in B2M...
...Roche (SIX:ROG; OTCQX:RHHBY), Basel, Switzerland U.S. Food and Drug Administration (FDA), Silver Spring, Md. Targets B2M...
BioCentury | Oct 19, 2018
Tools & Techniques

Allogeneic CARs on the horizon

...known to elicit host immune responses, such as CD52, MHC molecules or the MHC component B2M...
...3) Cellectis and partners Sorrento Therapeutics Inc. (NASDAQ:SRNE) and Celularity Inc. are knocking out B2M. B2M...
...plc Allogene Therapeutics Inc. Atara Biotherapeutics Inc. Cell Medica Ltd. Cellectis S.A. Celyad S.A. CRISPR Therapeutics AG Editas Medicine Inc. Precision Therapeutics Inc. Beta-2 microglobulin (B2M) Major...
BioCentury | Dec 5, 2017
Distillery Therapeutics

Cancer

...model of melanoma, knockout of the MHCI component B2M decreased tumor growth compared with normal B2M...
...malignancies. TARGET/MARKER/PATHWAY: Major histocompatibility complex class I (MHCI); leukocyte immunoglobulin-like receptor B1 (LILRB1); β-2 microglobulin (B2M...
BioCentury | Nov 29, 2017
Preclinical News

Researchers identify second macrophage inhibitory pathway as target for cancer immunotherapy

...of MHCI and resistance to anti-CD47-induced phagocytosis by macrophages. Knockout of the MHCI component beta-2 microglobulin (B2M...
...of both CD47 and B2M decreased tumor growth compared with knockout of either CD47 or B2M...
...falls within the IP (see BioCentury Innovations, Aug. 25, 2016) . Jennie Walters Forty Seven Inc. Stanford University Beta-2 microglobulin (B2M) CD47 Major...
BioCentury | Mar 23, 2017
Translation in Brief

Precision-engineered CARs

...a different promoter, and T cells with the CAR construct inserted at the β-2 microglobulin (B2M...
...with CRISPR/Cas9 enhances tumour rejection." Nature (2017) Karen Tkach, Senior Writer Cellectis S.A. Memorial Sloan Kettering Cancer Center Beta-2 microglobulin (B2M) CD19 T...
BioCentury | Sep 12, 2016
Emerging Company Profile

Age factors

...plasma factors, including chemokine CC motif ligand 11 ( CCL11 ; eotaxin-1 ) and beta-2 microglobulin (B2M...
...will initially focus on blocking or reducing degenerative factors in aged plasma, including CCL11 and B2M...
...declined to comment on bertilimumab. Alkahest also is exploring methods of removing plasma factors, including B2M...
BioCentury | May 2, 2016
Emerging Company Profile

Forward compatibility

...by homologous recombination. To create universal cell lines, the company replaces the gene for beta-2 microglobulin (B2M...
...required to bring class I HLAs to the cell surface, with a gene encoding the B2M...
BioCentury | Oct 22, 2014
Politics & Policy

FDA backs further study of kidney biomarkers

FDA issued its first Letter of Support for two kidney biomarkers identified by the Predictive Safety Testing Consortium (PSTC) of the Critical Path Institute (C-Path). Elevated levels of the two biomarkers, osteopontin (OPN) and neutrophil...
Items per page:
1 - 10 of 33